The number of people requiring treatment for Neglected Tropical Diseases (NTDs) decreased from 2.19 to 1.65 billion between 2010 and 2021 – an impressive 25
GENEVA, Nov 30: A new, single-dose oral treatment for sleeping sickness is 95 per cent effective in adults and adolescents, regardless of disease stage, and could be a key factor in eliminating disease transmission by 2030, according to a study published in The Lancet Infectious Diseases. Developed by not-for-profit Drugs for Neglected Diseases initiative (DNDi) and Sanofi, acoziborole, unlike current treatments for sleeping sickness, does not require multiple days of treatment, hospitalisation or highly skilled health personnel, the researchers said. […]
Success rates of up to 95% have been reported from the results of Phase II/III trials investigating the safety and efficacy of a single dose of acoziborole for the treatment of sleeping sickness.